Sharing An Innate Desire To Address Inflammation: Novartis And IFM Team Up

Today Novartis announced the acquisition of IFM Therapeutics ’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM

Source: Forbes.com Healthcare News - April 1, 2019 Category: Pharmaceuticals Authors: Bruce Booth, Contributor Source Type: news